3041-LB: Insulin Secretion Dynamics after Roux-en-Y Gastric Bypass and Their Association with Post-bariatric Hypoglycemia
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-3041-lb ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von ELAHEH MOHAMMADI und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Roux-en-Y gastric bypass (RYGB) is an effective treatment for obesity and type 2 diabetes but may lead to post-bariatric hypoglycemia (PBH). This study investigates how insulin secretion dynamics differ between post-RYGB patients with and without hypoglycemia by identifying key model parameters.
Methods
Insulin secretion parameters were identified using plasma glucose, insulin, and C-peptide concentrations during a mixed-meal tolerance test in three cohorts from clinical study NCT04428866: 11 controls, 18 post-RYGB without hypoglycemia, and 20 post-RYGB with hypoglycemia. Model identification used a forcing-function strategy.
Results
Models adequately captured experimental data across groups, with joint insulin-C-peptide normalized RMSE of 0.60 (0.28) in Controls, 0.84 (0.18) in RYGB-noPBH, and 0.92 (0.36) in RYGB-PBH. Post-RYGB subjects exhibited faster meal absorption (lower τ) and reduced insulin clearance (lower γ) vs. controls. Meal-driven insulin secretion (β) increased after surgery, whereas glucose-driven secretion (a) decreased in RYGB subjects without PBH but remained unchanged in those with PBH (Figure 1).
Conclusion
PBH appears to arise when meal-driven insulin secretion increases while glucose-driven secretion remains unchanged. Findings can be incorporated into in-silico platforms to support development and testing of therapeutic strategies for PBH. Disclosure E. Mohammadi: None. A. El Fathi: Research Support; Current; Tandem Diabetes Care, Inc. Research Support; Ended; Novo Nordisk A/S. L. Pei: None. H. Saeed: None. M.E. Patti: Other - My institution receives research funding for clinical trial.; Current; Recordati S.p.A, Amylyx. Other - Data Safety Monitoring Board; Current; Fractyl Health, Inc. B. Kovatchev: Research Support; Current; Dexcom, Inc. Other - Patent royalties handled by the UVA Licensing and Ventures Group; Current; Dexcom, Inc. Research Support; Current; Tandem Diabetes Care, Inc. Other - Patent royalties handled by the UVA Licensing and Ventures Group; Current; Tandem Diabetes Care, Inc. Research Support; Ended; Novo Nordisk. Other - Patent royalties handled by the UVA Licensing and Ventures Group; Ended; Novo Nordisk, Sanofi. M. Breton: Research Support; Current; Tandem Diabetes Care, Inc. Advisory Panel; Current; Tandem Diabetes Care, Inc. Other - IP royalties; Current; Tandem Diabetes Care, Inc. Research Support; Current; Dexcom, Inc. Other - IP royalties; Current; Dexcom, Inc. Speaker's Bureau; Current; Sinocare, Tandem Diabetes Care, Inc. Other - IP royalties; Current; Sanofi. Research Support; Ended; Novo Nordisk. Other - IP royalties; Ended; Novo Nordisk. Consultant; Current; Boydsense, Roche Diabetes Care. Funding National Institutes of Health (R01DK137518)
Zitieren
APA
MOHAMMADI, E., FATHI, A. E., PEI, L., SAEED, H., PATTI, M. E., KOVATCHEV, B., & BRETON, M. (2026). 3041-LB: Insulin Secretion Dynamics after Roux-en-Y Gastric Bypass and Their Association with Post-bariatric Hypoglycemia. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-3041-lb
Vancouver
MOHAMMADI E, FATHI AE, PEI L, SAEED H, PATTI ME, KOVATCHEV B, et al. 3041-LB: Insulin Secretion Dynamics after Roux-en-Y Gastric Bypass and Their Association with Post-bariatric Hypoglycemia. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-3041-lb
BibTeX
@article{MOHAMMADI2026,
author = {MOHAMMADI, ELAHEH and FATHI, ANAS EL and PEI, LEI and SAEED, HAMAYLE and PATTI, MARY E. and KOVATCHEV, BORIS and BRETON, MARC},
title = {3041-LB: Insulin Secretion Dynamics after Roux-en-Y Gastric Bypass and Their Association with Post-bariatric Hypoglycemia},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-3041-lb}
}
EUVIMED